Baseline characteristics of the included trials
| Trial ID | Year | Condition(s) | Max follow-up | Number randomised | Mean age | %-Female | % on beta-blockers | % on calcium channel blockers |
| Adel | 2016 | CAD | 30 days | 45 | 57.3 | 35.6 | 35.6 | NR |
| Ageev | 2010 | CAD | 6 mo | 50 | 63.8 | 8.0 | NR | NR |
| ASSOCIATE | 2009 | CAD | 4 mo | 889 | 59.9 | 15.6 | NR | NR |
| Barilla | 2016 | CAD +HF | 6 mo | 58 | 55.4 | 32.8 | NR | NR |
| BEAUTIFUL | 2008 | CAD +HF | 35 mo | 10 917 | 65.2 | 17.1 | 86.9 | NR |
| Borer | 2003 | CAD | 2 wks | 360 | NR | NR | NR | NR |
| Cay | 2011 | CAD | 30 days | 120 | NR | NR | NR | NR |
| Chen | 2019 | CAD | NR | 100 | 64.2 | 44.0 | NR | NR |
| CL2-16257-060 | 2009 | AMI | 24 hours | 75 | 59.4 | 21.8 | 34.9 | NR |
| CL2-16257-096 | 2014 | CAD | 3 wks | 14 | 62.9 | 14.3 | 100.0 | NR |
| CL3-16257-064 | 2010 | CAD | 6 wks | 427 | 59.4 | 31.2 | NR | 23.1 |
| CL3-16257-067 | 2015 | CAD | 36 mo | 97 | 63.5 | 42.2 | 73.2 | NR |
| CL3-16257-068 | 2012 | CAD | 6 wks | 1277 | 60.9 | 12.5 | NR | 100.0 |
| Di | 2020 | CAD | 3 mo | 90 | 69.3 | 37.8 | NR | NR |
| Dillinger | 2015 | CAD | 3 wks | 12 | 63.3 | 8.3 | 100.0 | 16.7 |
| Gao | 2017 | CSA | 3 mo | 80 | NR | NR | NR | NR |
| Gloekler | 2014 | CAD | 6 mo | 46 | 64.0 | 10.9 | 58.7 | 17.4 |
| Hao | 2016 | CAD | 3 mo | 32 | NR | NR | NR | NR |
| He | 2019 | CAD +HF | 6 mo | 68 | 64.8 | 47.1 | NR | NR |
| Hohneck | 2018 | CAD | 6 mo | 26 | 61.8 | 26.9 | 73.1 | 15.4 |
| Hu | 2018 | CAD +HF | NR | 169 | NR | NR | NR | NR |
| Huang | 2018 | CAD | 3 mo | 88 | NR | NR | NR | NR |
| Huang (WF) | 2017 | CAD | 3 mo | 85 | NR | NR | NR | NR |
| Kadro | 2015 | CAD | 6 mo | 50 | NR | NR | NR | NR |
| Lamendola | 2011 | CAD | 1 mo | 20 | 50.0 | 75.0 | NR | NR |
| Naji | 2014 | CAD | 1 mo | 78 | NR | NR | 60.3 | NR |
| Nguyen | 2018 | CAD +HF | NR | 19 | 57.5 | 15.8 | 94.7 | NR |
| RIVENDEL | 2016 | CAD | 2 mo | 70 | 69.5 | 22.9 | 58.6 | 10.0 |
| RIVIERA | 2012 | CAD | 30 days | 27 | 61.5 | 7.4 | 0.0 | 0.0 |
| Sallam | 2016 | CAD +HF | 3 mo | 100 | 63.5 | 30.0 | NR | NR |
| Sayganov | 2010 | CAD +HF | NR | 40 | 66.5 | 40.0 | NR | NR |
| Shavarov | 2015 | AMI | 14 days | 98 | 68.3 | 36.7 | 100.0 | NR |
| SIGNIFY | 2014 | CAD | 27.8 mo | 19 102 | 65.0 | 27.6 | 83.1 | 26.8 |
| Steg | 2013 | CAD | 4 mo | 124 | 59.4 | 22.5 | 32.3 | NR |
| Taccheri | 2014 | CAD | 12 mo | 90 | NR | NR | NR | NR |
| Tagliamonte | 2019 | CAD | 1 mo | 41 | 66.0 | 39.0 | NR | NR |
| Tatarchenko | 2008 | CAD +HF | 6 mo | 59 | 57.3 | NR | NR | NR |
| Vasyuk | 2009 | CAD | 6 mo | 22 | 56.2 | NR | NR | NR |
| Vatinian | 2015 | CAD | 6 mo | 52 | NR | NR | NR | NR |
| Villano | 2012 | CAD | 1 mo | 31 | NR | NR | NR | NR |
| Wang | 2019 | CAD +HF | 6 mo | 88 | 65.0 | 44.3 | NR | NR |
| Wang | 2018 | CAD | 3 mo | 80 | NR | NR | NR | NR |
| Zhang | 2018 | CAD | 4 mo | 62 | NR | NR | NR | NR |
| Zhang | 2019 | CAD +HF | 2 mo | 60 | 64.2 | 57.0 | NR | NR |
| Zhang | 2020 | CAD +HF | 6 mo | 85 | 64.4 | 36.5 | NR | NR |
| Zhao | 2017 | CAD | 3 mo | 120 | NR | NR | NR | NR |
| Zhou | 2019 | CAD | 4 mo | 90 | 61.4 | 42.2 | NR | NR |
AMI, acute myocardial infarction; ASSOCIATE, Efficay of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial (reference 46); CAD, coronary artery disease; HF, heart failure; mo, months; NR, not reported; RIVENDEL, Heart rate reduction by ivabradine for improvement of endothelial function in patients with coronary artery disease: the RIVENDEL study (reference 41); RIVIERA, Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: a pilot study (reference 31); wks, weeks.